Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Daponte, Antonio ^a   Signoriello, Simona ^b   Maiorino, Luigi ^c   Massidda, Bruno ^d   Simeone, Ester ^a   Grimaldi, Antonio Maria ^a   Caracò, Corrado ^a   Palmieri, Giuseppe ^e   Cossu, Antonio ^f   Botti, Gerardo ^a   Petrillo, Antonella ^a   Lastoria, Secondo ^a   Cavalcanti, Ernesta ^a   Aprea, Pasquale ^a   Mozzillo, Nicola ^a   Gallo, Ciro ^b   Comella, Giuseppe ^a   Ascierto, Paolo Antonio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c San Gennaro Hospital   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e CNR   (Italy)

^f UNIVERSITY HOSPITAL OF SASSARI   (Italy)

Author keywords

Dacarbazine; Fotemustine; Interferon ; Melanoma

Indexed keywords

ALPHA2B INTERFERON; DACARBAZINE; FOTEMUSTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HAIR LOSS; HEART DISEASE; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; HUMANS; INTERFERON-ALPHA; MELANOMA; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS;

EID: 84874721742     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-38     Document Type: Article

References (29)

1. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62:220-241. 10.3322/caac.21149, 22700443.
2. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008, 26:527-534. 10.1200/JCO.2007.12.7837, 18235113.
3. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990, 66:1873-1878. 10.1002/1097-0142(19901101)66:9<1873::AID-CNCR2820660904>3.0.CO;2-5, 2224783.
4. Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkany M, Bertrand P, Bizzari JP. Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest 1994, 12:414-420. 10.3109/07357909409038234, 8032964.
5. Del Vecchio M, Mortarini R, Canova S, el Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, Bedognetti D, Queirolo P, Morosini P, Perrone T, Bajetta E, Anichini A. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010, 16:5862-5872. 10.1158/1078-0432.CCR-10-2363, 21030496.
6. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004, 22:1118-1125. 10.1200/JCO.2004.04.165, 15020614.
7. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 2008, 6:62. 10.1186/1479-5876-6-62, 2605741, 18954464.
8. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM. Neoadjuvant treatment of regional stage IIIb melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006, 24:3164-3167. 10.1200/JCO.2005.05.2498, 16809739.
9. Gogas H, Ioannovich J, Dafni U, Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354:709-718. 10.1056/NEJMoa053007, 16481638.
10. Stuckert JJ, Tarhini AA, Lee S, Sander C, Kirkwood JM. Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696 [abstract]. J Clin Oncol 2007, 25:473S.
11. Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caracò C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 2010, 8:76. 10.1186/1479-5876-8-76, 2936304, 20712892.
12. Wang W, Edington HD, Rao UN, Jukic DM, Radfar A, Wang H, Kirkwood JM. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 2007, 13:1523-1531. 10.1158/1078-0432.CCR-06-1387, 17332298.
13. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007, 13:2422-2428. 10.1158/1078-0432.CCR-06-1805, 17438101.
14. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007, 4:e176. 10.1371/journal.pmed.0040176, 1865558, 17488182.
15. Simons DL, Lee G, Kirkwood JM, Lee PP. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med 2011, 9:52. 10.1186/1479-5876-9-52, 3114759, 21545749.
16. Wheatley K, Ives N, Eggermont A, Kirkwood J, Cascinelli N, Markovic SN, Hancock B, Lee S, Suciu S, . on behalf of International Malignant Melanoma Collaborative Group Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials [abstract]. J Clin Oncol 2007, 25:478S. on behalf of International Malignant Melanoma Collaborative Group.
17. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102:493-501. 10.1093/jnci/djq009, 20179267.
18. Comella P, Daponte A, Casaretti R, Ionna F, Fiore F, Presutti F, Frasci G, Caponigro F, Gravina A, Parziale AP, Mozzillo N, Comella G. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in the treatment of advanced melanoma. Eur J Cancer 1997, 33:1326-1329. 10.1016/S0959-8049(97)00120-2, 9301463.
19. Daponte A, Ascierto PA, Gravina A, Melucci MT, Palmieri G, Comella P, Cellerino R, DeLena M, Marini G, Comella G, . Italian Cooperative Oncology Group Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. Cancer 2000, 89:2630-2636. 10.1002/1097-0142(20001215)89:12<2630::AID-CNCR16>3.0.CO;2-Z, 11135225, Italian Cooperative Oncology Group.
20. Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, Giannotti B, Queirolo P, Tribbia G, Bernengo MG, et al. Multicentre randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alpha 2a in the treatment of advanced melanoma. J Clin Oncol 1994, 12:806-811.
21. Miller AB, Hoogstraten B, Staquet M, Winken AS. Reporting results on cancer treatment. Cancer 1981, 47:207-214. 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6, 7459811.
22. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003, 4:748-759. 10.1016/S1470-2045(03)01280-4, 14662431.
23. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 3549297, 20525992.
24. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, . BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516. 10.1056/NEJMoa1103782, 3549296, 21639808, BRIM-3 Study Group.
25. Robert C, Thomas L, Bondarenko I, O'Day S, JW MD, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526. 10.1056/NEJMoa1104621, 21639810.
26. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012, 13:879-886. 10.1016/S1470-2045(12)70324-8, 22894884.
27. Wolchok JD, Hoos A, O'Day S, Weber JS, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420. 10.1158/1078-0432.CCR-09-1624, 19934295.
28. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703. 10.1056/NEJMoa1210093, 3549295, 23020132.
29. Ascierto PA, Streicher HZ, Sznol M. Melanoma: a model for testing new agents in combination therapies. J Transl Med 2010, 8:38. 10.1186/1479-5876-8-38, 2873374, 20406483.